Clinical Trial Update: Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns [Phase 2]

View source ↗

Summary

A phase 2 clinical trial exploring adjuvant aumolertinib after resection for resectable stage I EGFRm+ non-small cell lung cancer with high-grade patterns.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Aumolertinib (Aumolertinib)

Snippet

Sponsor: Baohui Han | Conditions: Lung Cancer | Phase 2 | Status: UNKNOWN